Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Asset Writedowns and Impairment (2017 - 2025)

Coherus Oncology (CHRS) has disclosed Asset Writedowns and Impairment for 9 consecutive years, with $12.5 million as the latest value for Q4 2025.

  • Quarterly Asset Writedowns and Impairment rose 68.96% to $12.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $20.3 million through Dec 2025, up 43.71% year-over-year, with the annual reading at $14.1 million for FY2025, 0.3% changed from the prior year.
  • Asset Writedowns and Impairment hit $12.5 million in Q4 2025 for Coherus Oncology, up from $500000.0 in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $48.2 million in Q4 2023 to a low of -$347000.0 in Q2 2023.
  • Historically, Asset Writedowns and Impairment has averaged $9.6 million across 5 years, with a median of $3.2 million in 2023.
  • Biggest five-year swings in Asset Writedowns and Impairment: plummeted 94.33% in 2023 and later soared 109.81% in 2024.
  • Year by year, Asset Writedowns and Impairment stood at -$92000.0 in 2021, then skyrocketed by 28360.87% to $26.0 million in 2022, then soared by 85.48% to $48.2 million in 2023, then tumbled by 84.72% to $7.4 million in 2024, then surged by 68.96% to $12.5 million in 2025.
  • Business Quant data shows Asset Writedowns and Impairment for CHRS at $12.5 million in Q4 2025, $500000.0 in Q3 2025, and $7.4 million in Q4 2024.